Infectiousness After 3 Days of Tamiflu for Influenza A

Duration of Viral Shedding on Oseltamivir

The Centers for Disease Control and Prevention indicates that viral shedding can continue throughout and even after the full treatment course of oseltamivir for influenza A, with patients potentially shedding susceptible viruses early in treatment and drug-resistant viruses later, including after 5-7 days of therapy 1, 2, 3, 4, 5.
The American Academy of Family Physicians notes that data on whether oseltamivir reduces viral shedding duration are mixed, with one study showing reduced viral shedding, but other studies not consistently demonstrating this reduction 1.

The Centers for Disease Control and Prevention recommends that standard isolation precautions should continue beyond 3 days of treatment, as viral shedding continues during and after treatment, suggesting ongoing transmission risk 1, 4.
The World Health Organization indicates that persons treated with oseltamivir can transmit both susceptible and resistant viruses during therapy, indicating that treatment does not eliminate infectiousness 1, 4, 5.

The American College of Physicians states that oseltamivir reduces symptom duration by approximately 1 day when started within 48 hours of illness onset, but this symptomatic improvement does not necessarily correlate with elimination of infectiousness 1, 2, 3, 6, 7.
The Infectious Diseases Society of America notes that the drug has not been demonstrated to prevent serious complications like bacterial or viral pneumonia, further suggesting its limitations in completely controlling viral replication 2, 3, 6.

The Centers for Disease Control and Prevention advises to continue isolation precautions even after 3 days of Tamiflu treatment, until at least 24-48 hours after fever resolution without fever-reducing medications and improvement of other symptoms 2, 3.
The American Academy of Family Physicians recommends to complete the full 5-day course of oseltamivir as prescribed to maximize viral suppression and reduce the risk of developing drug-resistant strains 1, 2, 3, 6, 7.